1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Metsera Enters Race With Potential Monthly GLP-1 Injection For Obesity

 
• By Alaric DeArment

Five months after its debut, the company plans to take its candidate, MET-097, into Phase IIb development.

• Source: Shutterstock

Metsera, Inc. is stepping into the rapidly growing ring of companies developing GLP-1 agonists for obesity with new Phase I data showing significant weight reduction as well as the potential for monthly dosing of its candidate, MET-097.

Privately held, New York-based biotech Metsera announced topline results on 24 September for MET-097, a long-acting injectable, fully biased GLP-1 receptor agonist, reporting that it achieved significant and durable weight loss

Key Takeaways

  • Metsera unveiled positive Phase I topline results for its injectable GLP-1 agonist, MET-097, showing 7.5% weight reduction after a month.

  • Results showing further reduction after 51 days indicate the potential for the drug to be dosed once monthly

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

More from R&D

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.